Hemispherx Biopharma's rather tortured history continues. It agreed to pay $2.75 million to investors who purchased or acquired Hemispherx common stock from March 14, 2012 through and Dec. 20, 2012. They alleged that Hemispherx representatives touted overal positive results from Ampligen’s clinical trials.
That's money that could have gone to Ampligen ME/CFS studies...(sigh)
That's money that could have gone to Ampligen ME/CFS studies...(sigh)